We observed that systemic CPG-1668 administration suppressed orthotopic prostate cancers, and this was associated with enhanced systemic immunity, supporting the utility of TLR9 agonists as a therapeutic strategy for prostate cancer. The gene discussed is TLR9; the disease is Familial prostate cancer.